GlassScriptPhysician profile
Mohamad B Taha
NPI 1992168496
$8,291.93
in general payments reported to CMS, 2019-2025
22 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.85 · 2022: $1,008 · 2023: $2,143 · 2024: $2,967 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,645 · Education: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,645.23 |
| Education | $587.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,867.07 | 2022-2025 | Avvigo Guidance System, Watchman Flx, Synergy |
| Abbott Laboratories | $1,386.03 | 2022-2025 | Ensite, Dragonfly Opstar, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $1,227.36 | 2021-2025 | Corevalve Evolut R, Resolute Onyx, Cobalt Dr Mri Surescan |
| Amgen INC. | $1,018.06 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $551.59 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.67 | 2022-2025 | Jardiance |
| Philips North America LLC | $246.74 | 2024 | (Bh4) Igt Devices Undivided, (Bq9) Coronary Ivus |
| Abiomed | $243.17 | 2024-2025 | Impella |
| W. L. Gore & Associates, INC. | $232.82 | 2022-2024 | Gore Cardioform Septal Occluder |
| Actelion Pharmaceuticals US, INC. | $180.28 | 2022-2024 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $175.09 | 2022-2023 | |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Stryker Corporation | $125.54 | 2025 | Flowtriever |
| Janssen Pharmaceuticals, INC | $104.17 | 2022-2024 | Xarelto |
| Pfizer INC. | $89.51 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $85.42 | 2022-2024 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.04 | 2022-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $46.63 | 2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $42.43 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $31.66 | 2023 | Definity |
| Astrazeneca Pharmaceuticals LP | $18.54 | 2024 | Farxiga |
| Ge Healthcare | $14.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.